The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy
Open Access
- 28 June 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13), 6932
- https://doi.org/10.3390/ijms22136932
Abstract
In the past decade, immunotherapies have been emerging as an effective way to treat cancer. Among several categories of immunotherapies, immune checkpoint inhibitors (ICIs) are the most well-known and widely used options for cancer treatment. Although several studies continue, this treatment option has yet to be developed into a precise application in the clinical setting. Recently, omics as a high-throughput technique for understanding the genome, transcriptome, proteome, and metabolome has revolutionized medical research and led to integrative interpretation to advance our understanding of biological systems. Advanced omics techniques, such as multi-omics, single-cell omics, and typical omics approaches, have been adopted to investigate various cancer immunotherapies. In this review, we highlight metabolomic studies regarding the development of ICIs involved in the discovery of targets or mechanisms of action and assessment of clinical outcomes, including drug response and resistance and propose biomarkers. Furthermore, we also discuss the genomics, proteomics, and advanced omics studies providing insights and comprehensive or novel approaches for ICI development. The overview of ICI studies suggests potential strategies for the development of other cancer immunotherapies using omics techniques in future studies.Keywords
Funding Information
- National Research Foundation of Korea (2018R1A6A1A03025108)
- Korea Health Industry Development Institute (HF20C0002)
This publication has 167 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cellsJCI Insight, 2013
- Cytokines in Cancer ImmunotherapyCancers, 2011
- Assessment of the Evolution of Cancer Treatment TherapiesCancers, 2011
- Revisiting cancer immunoediting by understanding cancer immune complexityThe Journal of Pathology, 2011
- Liquid chromatography mass spectrometry-based proteomics: Biological and technological aspectsThe Annals of Applied Statistics, 2010
- FiehnLib: Mass Spectral and Retention Index Libraries for Metabolomics Based on Quadrupole and Time-of-Flight Gas Chromatography/Mass SpectrometryAnalytical Chemistry, 2009
- Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodiesBlood, 2008
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002